Dina Ramadane's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q1 2025
Question
Dina Ramadane, on for Jason Gerberry, asked where seizure freedom fits within the statistical hierarchy for X-TOLE2 and about assumptions for this endpoint. She also inquired about the lead indication selection for XEN1120 and the desired pharmacology profile from its Phase I trial.
Answer
President and CEO Ian Mortimer stated that for XEN1120, the Phase I trial will assess PK and safety, with the goal of advancing into a proof-of-concept study in pain. Chief Medical Officer Dr. Chris Kenney clarified that seizure freedom is not in the statistical hierarchy for the double-blind portion of the study, as it's an endpoint best measured over a longer term, making the open-label extension data the primary focus for that outcome.